Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Suspended 1Completed 1

Sponsor Class

OTHER 7OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 2Triple Negative Breast Neoplasms 1Small Cell Lung Cancer Extensive Stage 1Pathologic Complete Response 1Oesophagogastric Cancer 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell, Marginal Zone 1HR+/HER2- Breast Cancer 1Congenital Abnormalities 1Breast Neoplasms 1

Interventions

Rituximab 3Vincristine 2Prednisone 2Epirubicin 2Cyclophosphamide 2zanubrutinib 1liposomal doxorubicin 1ibrutinib 1durvalumab 1Vinorelbine 1Thalidomide 1Radiotherapy 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Mitoxantrone 1Methotrexate 1Lenalidomide 1Human Papillomavirus Recombinant Vaccine nonavalent 1Dexamethasone 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Lymphoma, Large B-Cell, Diffuse × Epirubicin × Clear all
NCT04214626 2025-11-19

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Henan Cancer Hospital

Phase 2 Completed
60 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04668365 2025-04-25

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Henan Cancer Hospital

Phase 2 Suspended
59 enrolled
Lymphoid

Congenital Abnormalities, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡